<SEC-DOCUMENT>0001193125-21-220172.txt : 20210721
<SEC-HEADER>0001193125-21-220172.hdr.sgml : 20210721
<ACCEPTANCE-DATETIME>20210721081628
ACCESSION NUMBER:		0001193125-21-220172
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210721
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210721
DATE AS OF CHANGE:		20210721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viracta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001061027
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943295878
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51531
		FILM NUMBER:		211102808

	BUSINESS ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007
		BUSINESS PHONE:		858-400-8470

	MAIL ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOSAIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUNESIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980501
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d160255d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): July&nbsp;21, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>VIRACTA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-51531</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">94-3295878</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>of incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Identification No.)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>2533 S Coast Hwy 101, Suite 210 Cardiff, California</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>92007</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (858)
<FONT STYLE="white-space:nowrap">400-8470</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report.) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.0001 par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>VIRX</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;21, 2021, Viracta Therapeutics, Inc. (the &#147;Company&#148;) issued a press release announcing that the U.S. Food and Drug
Administration provided clearance of the Company&#146;s Investigational New Drug application for a Phase 1b/2 clinical trial of the Company&#146;s combination product candidate of nanatinostat and valganciclovir in patients with Epstein-Barr
Virus-Positive (&#147;EBV+&#148;) recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The press release is
attached as Exhibit 99.1 to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d) Exhibits </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d160255dex991.htm">Press Release, dated July&nbsp;21, 2021 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July&nbsp;21, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel Chevallard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Chevallard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Chief Operating Officer and Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d160255dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g160255g80b75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr
Virus-Positive (EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>) Solid Tumors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Third combination trial with nanatinostat
and valganciclovir broadens scope beyond EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> lymphoproliferative disorders </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Trial initiation expected in H2 2021 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PR Newswire, San Diego, July</I><I></I><I>&nbsp;21, 2021 &#150; </I><U>Viracta</U> Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company
targeting virus-associated malignancies, today announced that&nbsp;the&nbsp;U.S. Food and Drug Administration&nbsp;(FDA) has cleared Viracta&#146;s Investigational New Drug (IND) application to proceed into a Phase 1b/2 trial in patients with EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP> recurrent or metastatic nasopharyngeal carcinoma <FONT STYLE="white-space:nowrap">(RM-NPC)</FONT> and other EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> solid tumors. The global Phase
1b/2 trial is designed to evaluate the safety and preliminary efficacy of Viracta&#146;s <FONT STYLE="white-space:nowrap">all-oral</FONT> combination regimen in advanced EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> solid tumors
(including EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> <FONT STYLE="white-space:nowrap">RM-NPC),</FONT> and in combination with the <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor pembrolizumab in EBV<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP> <FONT STYLE="white-space:nowrap">RM-NPC.</FONT> Initiation of the trial is expected in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Clearance of this IND application is a crucial milestone that underscores the broader applicability of our therapeutic approach to treating patients
with <FONT STYLE="white-space:nowrap">EBV-associated</FONT> malignancies,&#148; said Lisa Rojkjaer, M.D., Chief Medical Officer of Viracta. &#147;EBV is the primary etiologic agent for NPC, one of the most commonly reported head and neck cancers
worldwide. Patients with <FONT STYLE="white-space:nowrap">RM-NPC</FONT> have a poor prognosis, with no standard treatment options for second or later lines of therapy, and median overall survival of less than 20 months. <FONT
STYLE="white-space:nowrap">PD-L1</FONT> is known to be highly expressed by NPC and preliminary response rates of <FONT STYLE="white-space:nowrap">20%-30%</FONT> have been reported with <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors for <FONT
STYLE="white-space:nowrap">RM-NPC.</FONT> Given the encouraging activity seen in our Phase 1b/2 trial of nanatinostat and valganciclovir in patients with EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> recurrent lymphomas, we now turn to
evaluating this combination in patients with other EBV<SUP STYLE="font-size:85%; vertical-align:top">+ </SUP>malignancies and explore potential synergies with checkpoint inhibition.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ivor Royston, M.D., President and Chief Executive Officer of Viracta, added, &#147;Expansion into our solid tumor program is an important component of our
clinical and corporate strategy, and one that could significantly expand our addressable patient population and unlock significant value to shareholders. Our <FONT STYLE="white-space:nowrap">all-oral</FONT> combination regimen represents a promising
new therapeutic approach to patients with EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> solid tumors, and I&#146;m very pleased that the program is progressing as planned and look forward to its continued advancement.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1b dose escalation portion of the trial is designed to evaluate safety, pharmacokinetics, and determine the recommended Phase 2 dosing regimen of
nanatinostat and valganciclovir for expansion in patients with EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> solid tumors. In Phase 2, the safety, preliminary efficacy and potential pharmacodynamic markers of nanatinostat and
valganciclovir together and in combination with pembrolizumab will be evaluated in EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> <FONT STYLE="white-space:nowrap">RM-NPC</FONT> patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Nanatinostat </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nanatinostat <FONT STYLE="white-space:nowrap">(VRx-3996)</FONT> is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta.
Nanatinostat is selective for specific isoforms of Class&nbsp;I HDACs, which is key to inducing viral genes that are epigenetically silenced in <FONT STYLE="white-space:nowrap">EBV-associated</FONT> malignancies. The nanatinostat and valganciclovir
combination is being investigated in multiple subtypes of relapsed/refractory EBV<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>&nbsp;lymphoma in two ongoing Phase 2 trials, one of which is a registration-enabling global, multicenter,
open-label basket trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Viracta Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Viracta is a precision oncology company targeting virus-associated malignancies. Viracta&#146;s proprietary investigational drug, nanatinostat, is currently
being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for <FONT STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma. Viracta is also pursuing application of its
inducible synthetic lethality approach in other <FONT STYLE="white-space:nowrap">EBV-associated</FONT> malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information please visit&nbsp;<U>www.viracta.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains
&#147;forward-looking&#148; statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the initiation, details and timeline for the Phase 1b/2 solid tumor trial and
related expectations; Viracta&#146;s ability to expand its pipeline and broaden the impact of its therapeutic approach; the potential synergistic interactions between Viracta&#146;s product candidate and pembrolizumab; Viracta&#146;s ability to
increase shareholder value; and other statements that are not historical facts.&nbsp;Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement
include, but are not limited to: Viracta&#146;s ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta&#146;s plans to develop and commercialize its product candidates, including all oral
combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta&#146;s planned clinical trials; the timing of the availability of data from Viracta&#146;s clinical trials; previous preclinical and clinical results may not be
predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta&#146;s plans to research, develop and commercialize its current and future product candidates; the clinical
utility, potential benefits and market acceptance of Viracta&#146;s product candidates; Viracta&#146;s ability to manufacture or supplying nanatinostat, valganciclovir and pembrolizumab for clinical testing; Viracta&#146;s ability to identify
additional products or product candidates with significant commercial potential; developments and projections relating to Viracta&#146;s competitors and its industry; the impact of government laws and regulations; Viracta&#146;s ability to protect
its intellectual property position; and Viracta&#146;s estimates regarding future expenses, capital requirements and need for additional financing in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These risks and uncertainties may be amplified by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which has caused significant economic
uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual
outcomes and results to differ materially from those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated by the forward-looking statements are included under the caption &#147;Risk Factors&#148; and elsewhere in Viracta&#146;s reports and other documents that Viracta has filed, or will
file, with the SEC from time to time and available at&nbsp;<U>www.sec.gov</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this communication are made
only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Investor Relations Contact: </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><B></B><B></B><B>Viracta Contact:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joyce Allaire</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dan Chevallard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LifeSci Advisors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer and Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>jallaire@lifesciadvisors.com</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>dchevallard@viracta.com</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(212) 915-2569</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(858) 771-4193</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SOURCE Viracta Therapeutics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g160255g80b75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g160255g80b75.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MPIXLU#5-6^QW@1U9"P95VE<?TKEH5G.5C@PF+G5G:1W(Z5VGJ;"T % !0 4
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.. "@ H * "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
